LUKE KOONG: Open Payments
NPI 1184250524 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,461 in 51 payments from 14 companies in 2025. Trend: 2023 $277 · 2024 $1,211 · 2025 $1,461
Food & beverage: $1,443Education: $19
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $541 |
| Novo Nordisk Inc | 7 | $209 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 11 | $204 |
| Amgen Inc. | 2 | $137 |
| Sumitomo Pharma America, Inc. | 5 | $85 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $61 |
| GlaxoSmithKline, LLC. | 2 | $43 |
| Exact Sciences Corporation | 2 | $41 |
| Hologic Sales and Service, LLC | 1 | $35 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $24 |
Products named: BREZTRI, Ozempic, JARDIANCE, AIRSUPRA, REPATHA, FARXIGA, GEMTESA, Kerendia.
Industry payments across TX — which companies pay providers there.
